CareLit Fachartikel

Mycophenolate mofetil: Experience in two adolescents with systemic lupus erythematosus and Wegener's granulomatosis and severe renal involvement

CM Gebauer, G Bürk, R Schille, V Schuster · Aktuelle Rheumatologie · 2003 · Heft 11

Dokument
1130927
CareLit-ID
Jahr
2003
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Aktuelle Rheumatologie
Autor:innen
CM Gebauer, G Bürk, R Schille, V Schuster
Ausgabe
Heft 11 / 2003
Seiten
–
Erschienen: 2003-11-10 00:00:00
ISSN
0341-051X
DOI
10.1055/s-2003-45058

Zusammenfassung

Introduction: Therapy of autoimmune diseases in childhood may be difficult due to prolonged requirement of toxic immunosuppressive agents. To induce remission, intravenous cyclophosphamide (CYC) or methylprednisolone are common. Infections and gonadal toxicity are major risks of CYC. In recent years new therapeutic agents have been developed. Reports on the use of mycophenolate mofetil (MMF, Cellcept®) in children with autoimmune diseases are rare. We report on our experience with MMF in severe renal disease in patients with systemic lupus erythematosus (SLE) and Wegener's granulomatosis. Case reports: Patient 1…

Schlagworte

Autoimmune Diseases Cyclophosphamide Azathioprine ANCA Antibodies Arthritis After Aktuelle Rheumatologie